|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MRPS25 |
Gene summary for MRPS25 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MRPS25 | Gene ID | 64432 |
| Gene name | mitochondrial ribosomal protein S25 | |
| Gene Alias | COXPD50 | |
| Cytomap | 3p25.1 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | P82663 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 64432 | MRPS25 | LP15 | Human | Oral cavity | LP | 4.33e-06 | 1.07e+00 | 0.2174 |
| 64432 | MRPS25 | SYSMH2 | Human | Oral cavity | OSCC | 1.21e-21 | 6.32e-01 | 0.2326 |
| 64432 | MRPS25 | SYSMH3 | Human | Oral cavity | OSCC | 2.17e-38 | 8.98e-01 | 0.2442 |
| 64432 | MRPS25 | SYSMH4 | Human | Oral cavity | OSCC | 2.13e-02 | 1.66e-01 | 0.1226 |
| 64432 | MRPS25 | SYSMH5 | Human | Oral cavity | OSCC | 6.59e-03 | 2.14e-01 | 0.0647 |
| 64432 | MRPS25 | SYSMH6 | Human | Oral cavity | OSCC | 7.77e-05 | 3.12e-01 | 0.1275 |
| 64432 | MRPS25 | P5_S10_cSCC | Human | Skin | cSCC | 4.24e-02 | 9.13e-02 | -0.299 |
| 64432 | MRPS25 | P1_cSCC | Human | Skin | cSCC | 2.06e-34 | 1.03e+00 | 0.0292 |
| 64432 | MRPS25 | P2_cSCC | Human | Skin | cSCC | 2.28e-18 | 5.05e-01 | -0.024 |
| 64432 | MRPS25 | P4_cSCC | Human | Skin | cSCC | 4.43e-21 | 5.63e-01 | -0.00290000000000005 |
| 64432 | MRPS25 | P10_cSCC | Human | Skin | cSCC | 4.25e-18 | 5.50e-01 | 0.1017 |
| 64432 | MRPS25 | male-WTA | Human | Thyroid | PTC | 9.21e-36 | 3.53e-01 | 0.1037 |
| 64432 | MRPS25 | PTC01 | Human | Thyroid | PTC | 2.65e-17 | 4.48e-01 | 0.1899 |
| 64432 | MRPS25 | PTC03 | Human | Thyroid | PTC | 6.44e-17 | 7.67e-01 | 0.1784 |
| 64432 | MRPS25 | PTC04 | Human | Thyroid | PTC | 1.42e-30 | 7.70e-01 | 0.1927 |
| 64432 | MRPS25 | PTC05 | Human | Thyroid | PTC | 1.06e-28 | 1.13e+00 | 0.2065 |
| 64432 | MRPS25 | PTC06 | Human | Thyroid | PTC | 1.50e-58 | 1.24e+00 | 0.2057 |
| 64432 | MRPS25 | PTC07 | Human | Thyroid | PTC | 7.57e-63 | 1.11e+00 | 0.2044 |
| 64432 | MRPS25 | ATC09 | Human | Thyroid | ATC | 2.16e-09 | 1.21e-01 | 0.2871 |
| 64432 | MRPS25 | ATC11 | Human | Thyroid | ATC | 2.53e-04 | 2.91e-01 | 0.3386 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MRPS25 | SNV | Missense_Mutation | novel | c.215N>T | p.Pro72Leu | p.P72L | P82663 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MRPS25 | SNV | Missense_Mutation | novel | c.8N>C | p.Met3Thr | p.M3T | P82663 | protein_coding | deleterious(0) | possibly_damaging(0.69) | TCGA-AA-A01R-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fluorouracil | PD |
| MRPS25 | SNV | Missense_Mutation | rs750588798 | c.388N>A | p.Gly130Ser | p.G130S | P82663 | protein_coding | deleterious(0.02) | probably_damaging(0.999) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MRPS25 | SNV | Missense_Mutation | rs762185729 | c.230N>A | p.Arg77Gln | p.R77Q | P82663 | protein_coding | tolerated(0.17) | benign(0.078) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MRPS25 | SNV | Missense_Mutation | rs750455782 | c.496N>A | p.Ala166Thr | p.A166T | P82663 | protein_coding | tolerated(0.27) | benign(0) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MRPS25 | SNV | Missense_Mutation | c.288N>T | p.Lys96Asn | p.K96N | P82663 | protein_coding | tolerated(0.25) | benign(0.003) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MRPS25 | SNV | Missense_Mutation | novel | c.215N>T | p.Pro72Leu | p.P72L | P82663 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| MRPS25 | SNV | Missense_Mutation | novel | c.206A>G | p.Asn69Ser | p.N69S | P82663 | protein_coding | deleterious(0) | probably_damaging(0.946) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MRPS25 | SNV | Missense_Mutation | novel | c.89N>C | p.Met30Thr | p.M30T | P82663 | protein_coding | deleterious(0) | benign(0.273) | TCGA-BK-A13B-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| MRPS25 | SNV | Missense_Mutation | rs143426565 | c.395N>A | p.Arg132Gln | p.R132Q | P82663 | protein_coding | tolerated(0.32) | benign(0.001) | TCGA-D1-A17Q-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |